Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

NYSE:MMM

3M Co. (MMM)

159.23
-2.40 (1.48%)
as of Jun 17, 2026, 8:00:00 pm Market Open.
197 watching
0
Investor Insights
star iconJun 17, 2026, 12:00 am

This summary was created by AI, based on 2 opinions in the last 12 months.

3M Co. is currently at a pivotal moment as it prepares to report its quarterly results. The newly appointed CEO is optimistic about the company's future, suggesting that a turnaround is on the horizon. However, some analysts urge caution, stating that while the immediate uncertainties have been resolved, the company now appears to be a lower-growth multi-industrial. They recommend taking profits and exploring investments in more robust alternatives within the industrial sector, such as Honeywell International Inc. or segments of other well-performing firms. As 3M navigates this transitional phase, investors are left weighing the potential benefits of the CEO's direction against the broader structural challenges of the business landscape.

consensus icon
Consensus
Mixed
valuation icon
Valuation
Fair Value
review icon
Similar
HON
TOP PICK
Involved in so many different product areas. Has good sustainability of growth. A good way to participate in the economic expansion.
TOP PICK
A really well diversified industrial with good global exposure. In a high growth area in the medical specialties area. Well positioned in Asia. Stock has dropped, so a good buying opportunity.
TOP PICK
Looking for slower growth in 2005, so fundamentals become crucially important. A very diversified company, possibly 20% next year.
DON'T BUY
Too pricey to buy.
TOP PICK
Top Short A shoulder/head/shoulder pattern.
TOP PICK
Trading near a 52 week low. Earnings were in line, but the market wasn't enamoured with them. Cyclical, but feels the cycle is going to be positive. Well diversified.
PAST TOP PICK
(Past top pick Mar 18/04. No change.) Still likes it. A well diversified industrial company. Sold off on the earnings release because they didn't exceed their guidance.
TOP PICK
Has been an underperforming company for many years. They are now getting more products through the R&D pipeline. Margins are going up. Benefits from a weaker US dollar.
PAST TOP PICK
(A top pick Mar 18/04. Up 4%.) Likes the exposure they have to Asia. With the general global recovery, this company continues to generate greater earnings.
PAST TOP PICK
(A top pick Feb 25/04. Up 11%.) Well positioned in an economic recovery and very well-positioned in Asia.
TOP PICK
Good exposure to Asia. Have a very strong medical technology side.
TOP PICK
Globally diversified. Has been in China for a decade, a high-growth area. Expect Asia will be the engine of growth.
DON'T BUY
Yield + 2%. Expensive. Will benefit from sales overseas.
TOP PICK
Has good new management/products. Should have a lot of cost cutting which will increase margins.
BUY
Showing 196 to 210 of 212 entries